E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Guillaume Richard-Carpentier,Hagop M. Kantarjian,Jeffrey L. Jorgensen,Sa A. Wang,Joseph D. Khoury,Farhad Ravandi,Nicholas J. Short,Rita Khouri,Koichi Takahashi,Maro Ohanian,Gautam Borthakur,Marina Konopleva,Naval Daver,Zeev Estrov,Yesid Alvarado,Nitin Jain,Tapan M. Kadia,Guillermo Garcia-Manero,Michelle Velasquez,Patrice Nasnas,Susan O'Brien,Elias Jabbour +21 more
TL;DR: The objective of this trial was to evaluate the safety and efficacy of blina in patients with B-ALL in CR with persistent or recurrent MRD+ and the primary endpoint was relapse-free survival (RFS).
Journal ArticleDOI
Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era
Young Kwang Chae,Hagop M. Kantarjian,Carlos Guillermo Romo,Clay Whitaker,Elias Jabbour,Susan O'Brien,Gautam Borthakur,Farhad Ravandi,Deborah A. Thomas,Sherry Pierce,Alfonso Quintás-Cardama,Jorge E. Cortes +11 more
TL;DR: Primary outcomes; progression free survival (PFS) and overall survival (OS) were defined as time from diagnosis of either BP or AP to treatment failure and death, respectively and only prior TKI use was associated with worse PFS.
Journal ArticleDOI
Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.
Sairah Ahmed,Rima M. Saliba,Marcos de Lima,Gabriela Rondon,Partow Kebriaei,Tobi Fisher,Elias Jabbour,Julianne Chen,Hagop M. Kantarjian,Paolo Anderlini,Amin M. Alousi,Chitra Hosing,Borje S. Andersson,Roy B. Jones,Muzaffar H. Qazilbash,Elizabeth J. Shpall,Sergio Giralt,Richard E. Champlin +17 more
TL;DR: In this article, the authors evaluated sequential therapy after a nonmyeloablative preparative regimen, designed to reduce risks of toxicity, graft-versus-host disease (GVHD) and treatment related mortality.
Journal ArticleDOI
Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis.
TL;DR: Evaluation of compliance to National Comprehensive Cancer Network (NCCN) and European LeukemiaNet (ELN) guidelines regarding monitoring frequency and switching practices in CML patients treated with IM in community practices finds majority of pts monitored according to both guidelines reported.
Journal ArticleDOI
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
Musa Yilmaz,Mansour Alfayez,Courtney D. DiNardo,Gautam Borthakur,Tapan M. Kadia,Marina Konopleva,Sanam Loghavi,Rashmi Kanagal-Shamanna,Keyur P. Patel,Elias Jabbour,Guillermo Garcia Manero,Naveen Pemmaraju,Sherry Pierce,Issa Ghayas,Nicholas J. Short,Guillermo Montalban-Bravo,Koichi Takahashi,Rita Assi,Ahmad S. Alotaibi,Maro Ohanian,Michael Andreeff,Jorge E. Cortes,Hagop M. Kantarjian,Farhad Ravandi,Naval Daver +24 more